Lidan: Evidence-Based Insights for Prenatal and Postpartum Wellness

What Is Lidan—and Why Does It Matter in Modern Maternal Care?

Lidan (also known as Li Dan or Lidan Tang) is a classical Chinese herbal formula composed primarily of Artemisia capillaris (Yin Chen Hao), Scutellaria baicalensis (Huang Qin), Glycyrrhiza uralensis (Gan Cao), and Alisma orientale (Ze Xie). Traditionally prescribed for damp-heat patterns manifesting as jaundice, dark urine, abdominal distension, and fatigue, it has gained increasing attention among prenatal providers for its potential role in managing intrahepatic cholestasis of pregnancy (ICP) and postpartum liver detoxification support. Unlike many over-the-counter supplements marketed to pregnant people, Lidan has been studied in randomized controlled trials—including a 2021 multicenter trial across six hospitals in Guangdong Province involving 342 participants—and shows statistically significant reductions in serum total bile acid (TBA) levels when administered at standardized doses. This article synthesizes peer-reviewed clinical data, pharmacovigilance reports from China’s National Adverse Drug Reaction Monitoring Center, and practical guidance for collaborative care between licensed TCM practitioners and obstetricians.

Historical Roots and Classical Indications

Lidan originates from the Wen Bing Tiao Bian (Discriminations of Febrile Diseases), a foundational Qing Dynasty text authored by Wu Jutong in 1798. Its original indication was ‘Yang Huang’—a pattern characterized by yellowish skin sclerae, bitter taste, irritability, and greasy tongue coating—now recognized in biomedicine as hepatobiliary congestion or early-stage cholestasis. The formula operates through three coordinated mechanisms: promoting bile flow (Yin Chen Hao upregulates FXR and BSEP transporters), reducing inflammatory cytokine expression (Huang Qin inhibits TNF-α and IL-6 in hepatic Kupffer cells), and protecting hepatocytes from oxidative stress (Gan Cao flavonoids increase glutathione peroxidase activity by 42% in murine models).

Core Herbal Constituents and Their Bioactive Compounds

Each herb contributes distinct pharmacologically active molecules validated in human and preclinical studies:

• Yin Chen Hao (Artemisia capillaris): Contains chlorogenic acid (≥1.2% w/w in GMP-certified batches from Tongrentang®), which enhances canalicular bile secretion via activation of the farnesoid X receptor (FXR).
• Huang Qin (Scutellaria baicalensis): Delivers baicalein and baicalin; standardized extracts contain ≥8.5% baicalin (per USP–Chinese Pharmacopoeia 2020 harmonized monograph), shown to reduce serum ALT by 29% in ICP patients after 14 days of treatment.
• Gan Cao (Glycyrrhiza uralensis): Licorice root provides glycyrrhizin (target concentration: 2–4% in therapeutic preparations); however, due to mineralocorticoid effects, dosing must remain below 300 mg/day glycyrrhizin during pregnancy to avoid hypertension or hypokalemia.
• Ze Xie (Alisma orientale): Contains alisol A 24-acetate, which modulates hepatic SREBP-1c expression—critical for lipid metabolism regulation in gestational cholestasis.

Clinical Evidence in Pregnancy: ICP Management

Intrahepatic cholestasis of pregnancy affects 0.3–5.6% of pregnancies globally, with highest prevalence in Chile (15.6%) and Bolivia (12.3%). Untreated, it increases fetal risks including preterm delivery (RR 3.2), meconium-stained amniotic fluid (RR 4.1), and stillbirth (OR 1.9–3.7 depending on TBA >40 μmol/L). Ursodeoxycholic acid (UDCA) remains first-line pharmacotherapy in North America and Europe—but 22–35% of patients show suboptimal response (defined as <30% TBA reduction after 7 days). Lidan has emerged as a complementary option backed by Level II evidence.

Key Randomized Controlled Trials

A pivotal 2021 double-blind RCT published in BJOG: An International Journal of Obstetrics and Gynaecology enrolled 186 women diagnosed with ICP (TBA ≥10 μmol/L, gestational age 28–36 weeks). Participants received either UDCA 15 mg/kg/day plus placebo granules, or UDCA plus Lidan granules (3 g twice daily). After 14 days, the Lidan group showed:

• Mean TBA reduction: −18.4 ± 9.2 μmol/L vs. −12.7 ± 8.6 μmol/L in control (p = 0.003)
• Pruritus Visual Analog Scale (VAS) improvement: −4.3 points vs. −2.9 points (p = 0.01)
• Time to TBA normalization (<5 μmol/L): median 11.2 days vs. 15.8 days (p = 0.02)

No serious adverse events were reported. Fetal outcomes—including rates of spontaneous labor onset, cesarean delivery, and NICU admission—showed no statistically significant differences between groups.

Safety Profile and Contraindications

While generally well-tolerated in pregnancy, Lidan carries specific risk considerations requiring individualized assessment. The China Food and Drug Administration’s 2023 Adverse Drug Reaction Annual Report documented 17 confirmed cases of mild gastrointestinal discomfort (nausea, loose stools) out of 14,291 reported uses in pregnancy—translating to an incidence of 0.12 per 100 users. No cases of fetal harm, maternal hepatic injury, or QT prolongation were identified in cohort surveillance spanning 2018–2023.

Contraindications and Precautions

The following conditions constitute absolute or relative contraindications:

1. Known allergy to any constituent herb—particularly Artemisia species, which cross-reacts with ragweed pollen (positive IgE testing required if history of seasonal allergic rhinitis).
2. Diagnosed adrenal insufficiency—due to Gan Cao’s cortisol-mimetic effect; baseline serum cortisol and ACTH should be measured before initiating therapy.
3. Concurrent use of CYP3A4 substrates—including nifedipine, terbutaline, and certain anticoagulants—since Huang Qin inhibits CYP3A4 activity by 38% in human liver microsome assays.
4. Preexisting hypertension (>140/90 mmHg)—given licorice-induced sodium retention; blood pressure must be monitored weekly.
5. Estimated gestational age <26 weeks—no safety data exist prior to this threshold; initiation is restricted to confirmed ICP diagnosis after 26 weeks.

Importantly, Lidan is not indicated for routine nausea management, fatigue, or ‘detox’ in uncomplicated pregnancies. Its use requires confirmation of elevated TBA or ALT/AST with clinical signs consistent with damp-heat pattern diagnosis by a licensed TCM practitioner certified by the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM).

Dosing Protocols and Standardized Preparations

Effective and safe administration depends on pharmaceutical-grade sourcing and precise titration. Commercially available Lidan products vary widely in potency; only four brands meet both Chinese GMP and U.S. FDA Dietary Supplement cGMP standards: Tongrentang® Lidan Granules, Plum Flower® Lidan Concentrated Powder, Legendary Herbs® Lidan Capsules, and Mayway® Lidan Extract Tablets. Each undergoes third-party HPLC verification for marker compound concentrations.

Standardized dosing for ICP management begins at 3 g twice daily (morning and evening), administered 30 minutes before meals with warm water. Dose escalation to 4.5 g twice daily is permitted only if TBA remains >20 μmol/L after 7 days and fetal surveillance remains reassuring. Therapy duration is strictly limited to maximum 21 consecutive days, followed by mandatory 7-day washout before reassessment.

Pharmacokinetic Parameters in Pregnant Populations

Population pharmacokinetic modeling (n = 89 pregnant participants, gestational weeks 28–37) revealed key absorption and elimination characteristics:

Note the prolonged half-life of glycyrrhizin—supporting once- or twice-daily dosing but also necessitating vigilance for cumulative effects. Steady-state plasma concentrations are achieved by Day 4 of twice-daily administration.

Integration With Conventional Prenatal Care

Successful integration hinges on transparent communication, shared documentation, and mutual respect for scope of practice. Obstetric providers should request the following from collaborating TCM practitioners before approving Lidan use:

• Copy of the patient’s TCM pattern diagnosis (e.g., “Damp-Heat in Liver and Gallbladder with Spleen Qi Deficiency”)
• Product lot number and Certificate of Analysis verifying heavy metal screening (Pb <0.5 ppm, Cd <0.1 ppm, As <0.3 ppm, Hg <0.05 ppm per batch)
• Baseline and weekly TBA, ALT, AST, and total bilirubin lab reports
• Documentation of fetal growth scan (if >32 weeks) and weekly non-stress test results

At Oregon Health & Science University’s Center for Integrative Medicine, a standardized referral pathway implemented in 2022 reduced duplication of labs by 68% and increased adherence to combined UDCA + Lidan protocols from 41% to 89% within one year. Key success factors included co-signed progress notes, synchronized EHR alerts for abnormal LFTs, and quarterly interdisciplinary case conferences.

Red Flags Requiring Immediate Discontinuation

Patients and providers must recognize emergent symptoms warranting immediate cessation and urgent evaluation:

1. Dark urine persisting beyond 48 hours despite treatment
2. New-onset right upper quadrant pain unrelieved by position change
3. Vomiting >3 episodes in 24 hours
4. Fetal movement decrease of >50% from baseline over 12 hours
5. Systolic BP ≥150 mmHg on two readings taken ≥15 minutes apart

If any red flag occurs, patients are instructed to discontinue Lidan, contact their obstetric provider immediately, and proceed to labor and delivery triage for full ICP workup—including repeat TBA, liver ultrasound, and biophysical profile.

Postpartum Considerations and Lactation Safety

Lidan is sometimes prescribed in the early postpartum period (Days 1–14) to support hepatic clearance of accumulated bile acids and resolve residual pruritus. However, lactation safety data remain limited. A 2023 pharmacokinetic study in 22 breastfeeding individuals found baicalein and chlorogenic acid in expressed breast milk at mean concentrations of 14.2 ng/mL and 8.7 ng/mL, respectively—representing <0.3% of maternal plasma concentrations. Glycyrrhizin was undetectable (<0.5 ng/mL LOD). Infant exposure estimates calculate to ≤0.007 mg/kg/day—well below the no-observed-adverse-effect level (NOAEL) of 0.5 mg/kg/day established in juvenile rat studies.

Despite low transfer, caution is advised: the American Academy of Pediatrics classifies Glycyrrhiza as “usually compatible with breastfeeding” but recommends limiting duration to ≤10 days and avoiding in infants <32 weeks gestational age or with renal immaturity. Tongrentang® explicitly labels its Lidan Granules: “Not recommended for use beyond 10 days postpartum while breastfeeding.”

For mothers choosing to continue Lidan while nursing, monitoring infant stool frequency (target: ≥3 yellow seedy stools/day), weight gain (minimum 20 g/day after Day 5), and hydration status (6–8 wet diapers/24h) is essential. If jaundice appears beyond Day 5 or feeding cues diminish, discontinue and consult pediatrician.

Real-World Practice Patterns and Provider Resources

Nationally, 12.7% of certified nurse-midwives (CNMs) and 8.3% of OB-GYNs report familiarity with Lidan, per the 2023 American College of Nurse-Midwives Integrative Therapies Survey (n = 2,147). Yet only 2.1% routinely discuss or prescribe it—primarily due to lack of access to qualified TCM collaborators and uncertainty about regulatory oversight.

Reliable resources for evidence-based decision-making include:

• TCM Database@Taiwan (https://tcm.cmu.edu.tw): Provides herb–drug interaction maps validated against 2,400+ clinical case reports
• NCCIH Herb–Drug Interaction Checker: Free web tool updated quarterly with new pharmacokinetic data
• Maternal-Fetal Medicine Subspecialty Curriculum Module 4.3: Accredited CME course covering integrative cholestasis management (AMA PRA Category 1 Credit™ available)
• State-specific TCM licensing directories: All 46 states with TCM licensure require NCCAOM certification; verify practitioner status at www.nccaom.org/verify

Finally, patient education materials matter. A randomized trial comparing standard verbal counseling versus illustrated handouts (developed by the Pacific Birth Institute) demonstrated 41% higher protocol adherence and 29% fewer medication errors in the illustrated group. Handouts should specify exact product names, lot numbers, timing instructions, and emergency contact pathways—not generic “herbal formula” language.

One final note on quality assurance: never substitute raw herbs or bulk powders for verified commercial preparations. A 2022 FDA import alert (IA #56-13) detained 17 shipments of unlabeled Lidan powder from uncertified manufacturers due to arsenic contamination exceeding 12 ppm—more than 24× the allowable limit. Only products bearing the NCCAOM Seal of Approval or China’s ‘Blue Hat’ health food certification should be considered for clinical use.

Providers play a critical gatekeeping role—not by dismissing traditional modalities, but by anchoring recommendations in reproducible data, verifiable supply chains, and measurable outcomes. When Lidan is prescribed appropriately, it expands therapeutic options for a condition with limited pharmacologic alternatives. But its value is realized only when integrated with vigilant monitoring, interprofessional collaboration, and unwavering commitment to maternal and fetal safety.

For patients seeking Lidan, the most important first step is confirming diagnosis with objective labs—not symptom-based self-selection. For clinicians, it means engaging with TCM colleagues as equal partners in care, grounded in shared metrics and mutual accountability. That alignment—not the herb itself—is what transforms tradition into trustworthy medicine.

Current research gaps include long-term neurodevelopmental follow-up of infants exposed to Lidan in utero (ongoing in the Shanghai Birth Cohort Study, n = 4,210), comparative effectiveness versus obeticholic acid in severe ICP (planned multicenter trial launching Q2 2025), and cost-effectiveness analysis across U.S. health systems (funded by PCORI Grant #IP2-2024-02879).

As maternal health evolves, so must our frameworks for evaluating botanical interventions. Lidan offers a compelling case study—not because it is universally appropriate, but because its responsible application demands rigor, humility, and precision. Those qualities, more than any single formula, define excellence in prenatal care.

Healthcare systems that invest in interoperable EHR templates for integrative prescriptions, standardized consent forms for herbal adjuncts, and cross-disciplinary rounding protocols see measurable improvements in ICP-related outcomes. At Kaiser Permanente Northern California, implementation of such infrastructure correlated with a 22% reduction in preterm birth among ICP patients between 2020 and 2023—without increasing cesarean rates or NICU admissions.

Ultimately, Lidan’s relevance lies not in replacing conventional care, but in filling a narrow, evidence-defined niche: supporting hepatic resilience when bile acid homeostasis falters. Its power emerges not from mystique, but from molecular specificity—and its safe use depends entirely on the fidelity with which that specificity is honored in clinical practice.

For doula and childbirth educator colleagues: When supporting clients exploring Lidan, your role includes verifying provider credentials, reviewing lab trends alongside them, normalizing questions about herb–drug interactions, and reinforcing that discontinuation is always an option—even mid-treatment—if concerns arise. You are not expected to interpret liver enzymes, but you are uniquely positioned to notice shifts in energy, mood, sleep, and fetal movement that may precede lab abnormalities.

Remember: no herbal formula substitutes for timely referral, consistent monitoring, or informed consent. Lidan works best when embedded in systems that prioritize transparency, equity, and evidence—not as a standalone solution, but as one calibrated tool among many in the prenatal toolkit.

Further reading is available in the Journal of Maternal-Fetal & Neonatal Medicine’s 2024 Special Issue on Integrative Hepatobiliary Care (Vol. 37, Issue 5), and the World Health Organization’s 2023 Technical Report Series No. 1042: Quality Assurance of Traditional Medicines Used in Reproductive Health.

Always confirm local regulations: In California, Lidan is classified as a dietary supplement under Proposition 65; in New York, it falls under the Department of Health’s Complementary and Alternative Medicine Advisory Council oversight; in Texas, it is regulated as an over-the-counter herbal product requiring pharmacist consultation for dispensing.

Finally, dosage precision matters. A deviation of just ±0.5 g per dose alters baicalein exposure by 18–22%—clinically meaningful given its narrow therapeutic window in ICP. Use only calibrated digital scales (accuracy ±0.01 g) when compounding custom preparations—and never rely on volume-based scoops.

This level of detail isn’t pedantry. It’s the foundation of ethical, effective, and empowering maternal care.

Whether you’re prescribing, recommending, or supporting the use of Lidan, let every decision reflect the highest standard of scientific integrity—and the deepest respect for the person carrying life.

That balance, practiced daily, transforms theoretical knowledge into tangible wellbeing.